News

Fresenius Kabi announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved OtulfiTM (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara® ** (ustekinumab). OtulfiTM is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis.

Fresenius Kabi announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment in chronic autoimmune diseases.

Tyenne^® is the first tocilizumab biosimilar by Fresenius Kabi with an intravenous and subcutaneous formulation approved by the FDA. The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients.

Tyenne^® provides a comprehensive, accessible, and high-quality treatment option for U.S. patients treated with tocilizumab.

Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO^® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.

Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend^®(pegfilgrastim-fpgk), the company’s biosimilar to Neulasta^® (pegfilgrastim), for use in patients at risk for febrile neutropenia

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.